Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 13;51(5):1361-1370.
doi: 10.1093/ije/dyac141.

SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant

Affiliations

SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant

Gloria D Chechet et al. Int J Epidemiol. .

Abstract

Background: Nigeria is Africa's most populated country. By November 2021 it had experienced three waves of SARS-CoV-2 infection. Peer-reviewed seroprevalence data assessing the proportion of the Nigerian population that have been infected were extremely limited.

Methods: We conducted a serosurvey in one urban site (n = 400) and one rural site (n = 402) in Kaduna State, Nigeria between 11 October 2021 and 8 November 2021. Z-tests were used to compare seroprevalence across age groups, locations and sexes. T tests were used to determine whether age or household size are associated with seropositivity. Associations between seropositivity and recent history of common Covid-19 symptoms were tested using logistic regression.

Results: SARS-CoV-2 antibodies were detected in 42.5% an 53.5% of participants at the urban and rural sites, respectively The overall age- and sex- stratified seroprevalence was 43.7% (42.2% for unvaccinated individuals). The data indicate an infection rate in Kaduna State ≥359-fold the rate derived from polymerase chain reaction-confirmed cases. In the urban site, seroprevalence among females and participants aged <20 was lower than other groups. Reporting loss of sense of taste and/or smell was strongly associated with seropositive status. Associations with seropositivity were also found for the reporting of dry cough, fever, headache, nausea and sore throat.

Conclusions: This study provides baseline SARS-CoV-2 seroprevalence in Kaduna State, Nigeria, immediately prior to the spread of the Omicron variant. It indicates that in October/November 2021, approximately 56% of the population did not have detectable antibodies, and population subgroups with particularly low seroprevalence remain. It highlights limitations in using PCR-confirmed cases to estimate infection rates. The data will inform public health strategies in Nigeria and other sub-Saharan African countries with limited SARS-CoV-2 seroprevalence data.

Keywords: Covid-19; Kaduna; Nigeria; SARS-CoV-2; seroprevalence.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Daily new confirmed COVID-19 cases per million people in Nigeria, 7-day rolling average, 4 March 2020 to 30 November 2021. (Source: Our World In Data.)

References

    1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157–60. - PMC - PubMed
    1. Ritchie H, Mathieu E, Rodes-Guirao L et al. Coronavirus Pandemic (COVID-19). 2020. http://ourworldindata.org/coronavirus (10 May 2022, date last accessed).
    1. Arora RK, Joseph A, Van Wyk J et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis 2021;21:E75–76. - PMC - PubMed
    1. Gudina EK, Ali S, Girma E et al. Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities. Lancet Glob Health 2021;9:E1517–27. - PMC - PubMed
    1. Nyagwange J, Kutima B, Mwai K et al. Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations. J Clin Virol 2022;146:105061. - PMC - PubMed

Publication types

Substances

Supplementary concepts